臺灣博碩士論文加值系統

目的：本研究主要是探討蝦紅素增補對年輕男性力竭運動後肌肉損傷程度的發炎及肝臟功能的損傷情形是否有保護作用。方法：本研究受試者共計13位(年齡：23.8 ± 4.8；身高：172.7 ± 6.0；體重：76.4 ± 11.9；BMI：25.5 ± 2.8)，使用雙盲交叉實驗設計，分為二階段共計15週，並將受試者依平衡次序法分為增補劑（蝦紅素）與安慰劑處理。第一階段受試者需每日增補增補劑及安慰劑各16 mg/day，連續增補五週，並利用固定式腳踏車力竭運動作為單次運動介入。進入排空期並交叉更換組別後，進行第二階段的增補及運動介入。所有受試者於增補前、後，空腹8小時安靜狀態下採集丙氨酸轉氨脢(glutamic pyruvic transaminase, GPT)、天門冬氨酸轉氨脢(glutamic-oaa transaminase, GOT)、肌酸激酶(creatine phospho kinase, CPK)、乳酸(lactate acid, LA)，並於單次力竭運動當下、運動後30分鐘、隔日(24小時)CPK、LA的血液數值。結果：增補劑與安慰劑於增補前、後安靜狀態下肝功能指標GOT(F= .074；P= .788)、GPT(F= .211；P= .650)，無顯著差異，相較於安慰劑，增補劑於增補前、後亦無下降趨勢(GOT增補前VS後：21.38 ± 6.54 VS 22.23 ± 6.62； GPT增補前VS後：27.77 ± 17.20 VS 29.31 ± 16.59)。於發炎指標中LA(運動前：F= .665；P= .423、力竭狀態：F= .123；P= .729及力竭後30分鐘：F= .496；P= .488)未達顯著差異。相較LA，CPK(運動前：F= .001；P= .974、力竭狀態：F= .009；P= .927及隔日：F= .086；P= .772)無顯著差異。結論：年輕健康男性，每日增補蝦紅素16 mg連續五週，不會影響肝功能。但對於運動過後因肌肉損傷所引起的發炎反應具有抑制與預防功能。

Objective: This study was to investigate whether astaxanthin supplementation has a protective effect on inflammation and liver function damage in young males after exhaustive exercise. Method: In this study 13 subjects young healthy males( age: 23.8 ± 4.8 years; height: 172.7 ± 6.0 cm; body weight: 76.4 ± 11.9 kg; BMI: 25.5 ± 2.8 lg/m2). They were designed using a double-blind crossover experiment and divided into two phases for a total of 15 weeks. Subjects were divided into experimental and control trail. In the first phase, subjects were given daily supplementation of astaxanthin and placebo for 16 mg/day, supplemented for five weeks, and using a stationary bicycle exhaustive exercise as a single exercise intervention. After entering the five-week emptying period and cross-changing the trial, the second phase of the supplement and exercise intervention will be carried out., all subjects were quiet before and after the supplement, 8 hours on an empty stomach glutamic-pyruvic transaminase (GPT), glutamic-oaa transaminase (GOT), creatine phospho kinase (CPK), lactic acid (LA) were collected. The blood values of CPK and LA in the current single exhaustive exercise, 30 minutes after exercise, and every other day (24 hours). Result: The experimental trial and the control trial had no significant difference in liver function GOT (F= .074; P= .788) and GPT (F= .211; P= .650） before and after supplementation. Compared with the control trial, the experimental trial there was no significant. before and after the addition (GOT supplementation before vs after: 21.38 ± 6.54 vs 22.23 ± 6.62; GPT supplementation vs. post: 27.77 ± 17.20 vs 29.31 ± 16.59). In the inflammatory, LA (pre-exercise: F= .665; P= .423, exhaustion state: F= .123; P= .729 and 30 minutes after exhaustion: F= .496; P= .488） no significant. Compared with LA, CPK (pre-exercise: F= .001; P= .974, exhaustion status: F= .009; P= .927 and after 24 hours: F= .086; P= .772) no significant. Conclusion: Young healthy males supplemented with astaxanthin 16 mg for five weeks without affecting liver function. However, it has an inhibitory and preventive function against inflammatory reactions caused by muscle damage after exercise.

誌謝 i
摘要 ii
目次 iv
表次 viii
圖次 ix
第一章 緒論 1
第一節 研究背景與動機 1
第二節 研究目的 3
第三節 研究假設 3
第四節 名詞操作型定義 3
第二章 文獻探討 5
第一節 蝦紅素 5
ㄧ、蝦紅素 5
二、蝦紅素對生理功能之影響 5
第二節 肝臟及其常見的損傷 7
ㄧ、肝臟生理構造 7
二、肝臟解毒 7
三、肝臟損害 8
第三節 骨骼肌發炎反應 10
ㄧ、肌肉損傷 10
二、發炎反應 11
第四節 增補蝦紅素對與肝功能、運動引起發炎反應之影響 13
ㄧ、蝦紅素與肝功能之影響 13
二、蝦紅素對於運動引起發炎反應之影響 20
第三章 研究方法與步驟 26
第一節 受試對象 26
第二節 實驗設計 26
第三節 實驗日期與地點 27
第四節 實驗器材 27
第五節 實施方法與流程 29
第六節 資料分析與方法 33
第四章 實驗結果 34
第一節 受試者基本資料 34
第二節 增補蝦紅素對身體組成之影響 35
第三節 增補蝦紅素對於肝功能之影響 37
第四節 增補蝦紅素抑制發炎反應之功效 38
第五章 討論 40
第一節 增補蝦紅素對於受試者身體質量之影響 40
第二節 增補蝦紅素對於肝臟功能之影響 43
第三節 增補蝦紅素抑制發炎反應之功效 45
第六章 結論與建議 47
第一節 結論 47
第二節 建議 47
參考文獻 48
中文文獻 48
英文文獻 49
附錄 55
一、受試者須知 55
二、健康狀態調查表 57
三、人體研究證明書 59

中文文獻
王健（2001）。運動疲勞的判定，運動生理週訊。檢自：www. epsport. idv. tw/epsport/mainep. aSp
吳家慶、謝伸裕（2008）。動態恢復強度對損傷肌肉之功能及跑步經濟性的影響。體育學報，41(4)，1-14。
郭堉圻、林正常（1999）。維生素C、E與自由基對運動表現的交互影響。中華體育季刊，12(4)，64-72。
郭堉圻、郭蕙蘭、劉宇珊（2017）。蝦紅素的生理機轉及對慢性疾病之效應。運動研究，26，33-42。
陳永展、陳坤檸（2005）。游泳運動訓練之生理生化檢測與應用。大專體育，80，197-201。
陳忠慶、金明央（1997）。急性發炎反應與延遲性肌肉酸痛的關係之探討。北體學報，6，227-240。
曾郁、許美智（2009）。蝦紅素對運動表現之影響。大專體育，105，144-150。
廖威彰（1997）。自由基與運動引起的肌肉傷害。中華體育季刊，11(3)，95-101。
劉振玉（1999）。運動訓練與肌酸激酶研究進展。天津體育學院學報，14(1)，30-32。
張世沛、陳碧蓮、李明憲、陳妤瑄（2015）。柔道選手訓練後肥胖指標與組織傷害指標的改變。大專體育學刊，17(3)，341-352。 
英文文獻
Aoi, W., Naito, Y., Sakuma, K., Kuchide, M., Tokuda, H., Maoka, T.,Yoshikawa, T. (2003). Astaxanthin limits exercise-induced skeletal & cardiac muscle damage in mice. Antioxidants & Redox Signaling, 5(1), 139-144.
Aoi, W., Naito, Y., Takanami, Y., Ishii, T., Kawai, Y., Akagiri, S.,Yoshikawa, T. (2008). Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification. Biochemical & Biophysical Research Communications, 366(4), 892-897.
Armstrong, R., Warren, G., & Warren, J. (1991). Mechanisms of exercise-induced muscle fibre injury. Sports Medicine, 12(3), 184-207.
Baralic, I., &jelkovic, M., Djordjevic, B., Dikic, N., Radivojevic, N., Suzin-Zivkovic, V., Pejic, S. (2015). Effect of astaxanthin supplementation on salivary IgA, oxidative stress, & inflammation in young soccer players. Evidence Based Complementary & Alternative Medicine, 2015, 1-9.
Chen, Y. Y., Lee, P. C., Wu, Y. L., & Liu, L. Y. (2015). In vivo effects of free form astaxanthin powder on anti-oxidation & lipid metabolism with high-cholesterol diet. Plos One, 10(8), 1-16.
Clarkson, P. M., & Hubal, M. J. (2002). Exercise-induced muscle damage in humans. The American Journal of Physical Medicine & Rehabilitation, 81(11), S52-S69.
Di Mascio, P., Murphy, M. E., & Sies, H. (1991). Antioxidant defense systems: the role of carotenoids, tocopherols, & thiols. The American Journal of Clinical Nutrition, 53(1), 194S-200S.
Ebbeling, C. B., & Clarkson, P. M. (1989). Exercise-induced muscle damage & adaptation. Sports Medicine, 7(4), 207-234.
Friedman, S. L. (2000). Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. Journal of Biological Chemistry, 275(4), 2247-2250.
Feng, Y., Chu, A., Luo, Q., Wu, M., Shi, X., & Chen, Y. (2018). The protective effect of astaxanthin on cognitive function via inhibition of oxidative stress & inflammation in the brains of chronic T2DM rats. Frontiers in Pharmacology, 9, 2-11.
Fleischmann, C., Horowitz, M., Yanovich, R., Raz, H., & Heled, Y. (2019). Asthaxanthin improves aerobic exercise recovery without affecting heat tolerance in humans. Frontiers in Sports & Active Living, 1, 13-22.
Gentile, C. L., Frye, M., & Pagliassotti, M. J. (2011). Endoplasmic reticulum stress & the unfolded protein response in nonalcoholic fatty liver disease. Antioxidants & Redox Signaling, 15(2), 505-521.
Goto, S., Kogure, K., Abe, K., Kimata, Y., Kitahama, K., Yamashita, E., & Terada, H. (2001). Efficient radical trapping at the surface & inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochimica et Biophysica Acta, 1512(2), 251-258.
Hahn, L., Chen, D., Eng, H., & Sung, J. (1984). Clinical & etiological studies of acute viral hepatitis in Taiwan. Journal of the Formosan Medical Association, 83(2), 149-155.
Higuera-Ciapara, I., Felix-Valenzuela, L., & Goycoolea, F. M. (2006). Astaxanthin: a review of its chemistry & applications. Critical Reviews in Food Science & Nutrition, 46(2), 185-196.
Ikeuchi, M., Koyama, T., Takahashi, J., & Yazawa, K. (2006). Effects of astaxanthin supplementation on exercise-induced fatigue in mice. Biological & Pharmaceutical Bulletin, 29(10), 2106-2110.
Janoff, A., & Carp, H. (1981). Proteases, antiproteases, & oxidants: pathways of tissue injury during inflammation. Monographs on Pathology of Laboratory Animals, 23, 62-82.
Jia, Y., Wu, C., Kim, J., Kim, B., & Lee, S. J. (2016). Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha & inhibition of PPAR gamma & Akt. The Journal of Nutritional Biochemistry, 28, 9-18.
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001). Lipid mediator class switching during acute inflammation: signals in resolution. Nature lmmunology, 2(7), 612-619.
Liska, D. J. (1998). The detoxification enzyme systems. Alternative Medicine Review, 3(3), 187-198.
Liu, H., Liu, M., Fu, X., Zhang, Z., Zhu, L., Zheng, X., & Liu, J. (2018). Astaxanthin prevents alcoholic fatty liver disease by modulating mouse gut microbiota. Nutrients, 10(9), 2-17.
Li, S., Takahara, T., Fujino, M., Li, X. K., & Takahara, S. (2018). Astaxanthin prevents ischemia-reperfusion injury of the steatotic liver in mice. Transplantation, 102, 443-444.
Maeda, S., Takeda, S., Mlyamoto, Y., Aurada, M., & Harada, M. (1985). Effects of gomisin A on liver functions in hepatotoxic chemicals-treated rats. The Japanese Journal of Pharmacology, 38(4), 347-353.
Malhi, H., & Kaufman, R. J. (2011). Endoplasmic reticulum stress in liver disease. Journal of Hepatology, 54(4), 795-809.
Manabe, E., H&a, O., Naito, Y., Mizushima, K., Akagiri, S., Adachi, S.,Yoshikawa, T. (2008). Astaxanthin protects mesangial cells from hyperglycemia‐induced oxidative signaling. Journal of Cellular Biochemistry, 103(6), 1925-1937.
Michalopoulos, G. K. (2007). Liver regeneration. Journal of Cellular Physiology, 213(2), 286-300.
Naito, Y., Uchiyama, K., Aoi, W., Hasegawa, G., Nakamura, N., Yoshida, N., Yoshikawa, T. (2004). Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biofactors, 20(1), 49-59.
Ni, Y., Nagashimada, M., Zhuge, F., Zhan, L., Nagata, N., Tsutsui, A., Ota, T. (2015). Astaxanthin prevents & reverses diet-induced insulin resistance & steatohepatitis in mice: A comparison with vitamin E. Scientific Reports, 5, 1-15.
Ohno, T., Shimizu, M., Shirakami, Y., Miyazaki, T., Ideta, T., Kochi, T.,Moriwaki, H. (2016). Preventive effects of astaxanthin on diethylnitrosamine‐induced liver tumorigenesis in C57/BL/KsJ‐db/db obese mice. Hepatology Research, 46(3), E201-E209.
Park, J. S., Chyun, J. H., Kim, Y. K., Line, L. L., & Chew, B. P. (2010). Astaxanthin decreased oxidative stress & inflammation & enhanced immune response in humans. Nutrition & Metabolism, 7(1), 2-10.
Pashkow, F. J., Watumull, D. G., & Campbell, C. L. (2008). Astaxanthin: a novel potential treatment for oxidative stress & inflammation in cardiovascular disease. The American Journal of Cardiology, 101(10), S58-S68.
Rengel, D., Dıez-Navajas, A., Serna-Rico, A., Veiga, P., Muga, A., & Milicua, J. (2000). Exogenously incorporated ketocarotenoids in large unilamellar vesicles. Protective activity against peroxidation. Biochimica et Biophysica Acta, 1463(1), 179-187.
Sattar, N., Forrest, E., & Preiss, D. (2014). Non-alcoholic fatty liver disease. British Medical Journal, 349(8), 1-8.
Turkez, H., Geyikoglu, F., & Yousef, M. I. (2013). Beneficial effect of astaxanthin on 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-induced liver injury in rats. Toxicology & Industrial Health, 29(7), 591-599.
Weiss, S. J. (1989). Tissue destruction by neutrophils. New England Journal of Medicine, 320(6), 365-376.
Wu, Y. C., Huang, H. H., Wu, Y. J., Manousakas, I., Yang, C. C., & Kuo, S. M. (2019). Therapeutic & protective effects of liposomal encapsulation of astaxanthin in mice with alcoholic liver fibrosis.International Journal of Molecular Sciences, 20(16), 2-26.
Xie, J. J., Chen, X., Niu, J., Wang, J., Wang, Y., & Liu, Q. Q. (2017). Effects of astaxanthin on antioxidant capacity of golden pompano (Trachinotus ovatus) in vivo & in vitro. Fisheries & Aquatic Sciences, 20(1), 2-8.
Yang, Y., Kim, B., Park, Y. K., Koo, S. I., & Lee, J. Y. (2015). Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. Biochimica et Biophysica Acta, 1850(1), 178-185.
Zhou, L., Gao, M., Xiao, Z., Zhang, J., Li, X., & Wang, A. (2015). Protective effect of astaxanthin against multiple organ injury in a rat model of sepsis. Journal of Surgical Research, 195(2), 559-567.